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Achalasia is a rare neurological deficit of the esoph-
agus that produces an impaired relaxation of the low-
er esophageal sphincter and decreased motility of the 
esophageal body. Achalasia is generally accepted to 
be a pre-malignant disorder, since, particularly in the 
mega-esophagus, chronic irritation by foods and bac-
terial overgrowth may contribute to the development of 
dysplasia and carcinoma. We present a case of a 
51-year-old man with achalasia combined with esoph-
ageal cancer who has had dysphagia symptoms for 
more than 20 years. Since there was a clinically high 
possibility of supraclavicular lymph node metastasis, 
concurrent chemoradiation therapy was scheduled. 
After the third cycle of chemoradiation therapy, trans- 
thoracic esophageolymphadenectomy was performed. 
Histopathological examination of the main esophagus 
specimen revealed no residual carcinoma. And the 
entire regional lymph node areas were free of carci-
noma except for one azygos metastatic lymph node. 
In summary, achalasia is a predisposing factor for 
esophageal squamous cell carcinoma. Although sur-
veillance endoscopy in achalasia patients is still con-
troversial, periodic screening for cancer development 
in long-standing achalasia patients might be advisable. 
(Gut and Liver 2009;3:329-333)
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INTRODUCTION
  Achalasia is a disease of unknown cause in which aper-
istalsis in the distal esophagus and a failure of relaxation 
of the lower esophageal sphincter (LES) occurs. Since the 
etiology is unclear, treatment focuses on reliving symp-
toms. Nonetheless, despite treatment, food stasis often 
persists, causing development of chronic inflammation, 
dysplasia and possibly esophageal cancer.
  The correlation between achalasia and esophageal can-
cer was first noted by Fagge in 1872.
1 Since this initial 
report, achalasia has frequently been described as a pre-
disposing factor for esophageal cancer.
2,3 When esoph-
ageal cancer develops in patients with underlying acha-
lasia, diagnosis tends to be in the more advanced stages 
of cancer, compared to cases with no achalasia, because 
both physicians and patients often regard symptoms such 
as dysphagia and chest discomfort as attributable to the 
achalasia, rather than to other causes. Therefore, addi-
tional approaches that would lead to earlier diagnosis 
might be pursued less aggressively. 
    Here we report a case of achalasia combined with 
esophageal cancer treated by concurrent chemoradiation 
therapy.
CASE REPORT
  A 51-year-old man was admitted to our hospital be-
cause of mild dysphagia. He was diagnosed as esophageal 
motor disorder at a local clinic when he was teenager. 
The symptoms, which occurred for for both solids and 
liquids simultaneously, had begun more than 20 years 
ago. And whenever swallowing solid or liquid diet, he al-330   Gut and Liver, Vol. 3, No. 4, December 2009
Fig. 1. (A, B) Endoscopic view 
of fungating mass lesion with di-
lated lower esophagus. (C) Fun-
gating mass at distal esophagus 
and dilated distal esophagus with 
bird-beak sign. (D) Follow-up 
endoscopy showing disappearance 
of the previous cancer mass 
after the third cycle of concu-
rrent chemoradiation therapy.
ways felt the food was retained in the esophagus in a mo-
ment and passing through after a few seconds. However, 
there was no epigastric pain or chest pain. Sometimes 
vomiting and regurgitation developed after meal. Above 
symptoms had continued for several decades without sig-
nificant change of their patterns and severities. Since his 
initial disagnosis at a local clinic, he did not go to hospi-
tal thereafter till this visit to our institute.
  Physical examination revealed a small, round, palpable 
mass at the right supraclavicular fossa and routine blood 
tests were unremarkable. The patient underwent upper 
gastroendoscopy, showing a fungating, exophytic mass le-
sion with an irregular and friable surface involving 90% 
of the luminal circumference at 42 cm from the upper in-
cisors, just above the gastroesophageal (GE) junction 
(Fig. 1A, B). The scope could be passed through the GE 
junction into the stomach body with mild resistance. 
Multiple biopsies were taken from the fungating mass, 
which allowed identification of squamous cell carcinoma 
upon histopathological examination. An esophagogram al-
so showed a fungating mass of approximately 9 cm at the 
distal esophagus, and a dilated thoracic esophagus with 
bird-beak sign (Fig. 1C). Based on these results, esoph-
ageal squamous cell carcinoma with achalasia was consid-
ered and esophageal manometric study and positron emis-
sion tomography- computed tomography (PET-CT) were 
undertaken. The result of manometry was compatible 
with achalasia, specifically simultaneous contraction 
(mean pressure 14.48 mm Hg) and incomplete lower 
esophageal sphincter relaxation. PET-CT showed a large, 
hypermetabolic mass lesion at distal esophagus which 
was compatible with esophageal cancer (Fig. 2A). 
Hypermetabolism at the right hilar lymph node area and 
the right supraclavicular lymph node were observed. 
Although the aspiration biopsy at the right supraclavicular 
lymph node was negative for malignancy, there was a 
clinically high possibility of lymph node metastasis. For 
this reason, concurrent chemoradiation therapy was sug-
gested instead of esophagectomy. By this time, the pa-
tient’s dysphagia symptoms had worsened, so dilation of 
the lower gastroesophageal junction was performed using 
a 30 mm achalasia balloon dilator (6 psi for 5 seconds, 
Boston Scientific Microvasive
Ⓡ, Natick, MA, USA). 
Dysphagia symptoms greatly improved after dilation. 
Thereafter, concurrent chemoradiation therapy of 800 
mg/m
2/d fluorouracil was administered by continuous in-
fusion on day 1 to 3, and cisplatin 80 mg/m
2 intrave-
nously on day 2. Radiotherapy was delivered in five daily 
fractions per week of 1.8 Gy over 5.5 weeks, for a total of 
50.4 Gy. Radiation fields also included the right supra-Park JC, et al: Achalasia Combined with Esophageal Cancer Treated by Concurrent Chemoradiation Therapy   331
Fig. 2. (A) Intense 
18
F-fluoro-
deoxyglucose (FDG) uptake is 
seen in the primary distal eso-
phagus lesion with right hilar 
lymph node area and in the 
right supraclavicular lymph node. 
(B) The right hilar lymph node 
shows no definite FDG uptake. 
The main esophageal mass with 
right supraclavicular lymph node 
shows a decrease in size and 
mild FDG uptake compared to 
previous imaging.
clavicular lymph node area. After the third cycle of che-
motherapy with radiation, followup PET-CT was under-
taken. The right hilar lymph node showed no definite 
18F-fluorodeoxyglucose (FDG) uptake. The main esoph-
ageal mass with the right supraclavicular lymph node 
demonstrated decreased size and mild FDG uptake, com-
pared to the previous analysis (Fig. 2B). The follow-up 
gastroendoscopy also showed disappearance of the distal 
esophageal mass, with mild erythematous mucosal change 
at the previous cancer site (Fig. 1D). The patient had no 
serious complications during the third cycle of concurrent 
chemoradiation therapy. He was informed about his dis-
ease status and trans-thoracic esophageolymphadenectomy 
was performed (Fig. 3A). Histopathological examination 
of the main esophagus specimen revealed no residual car-
cinoma and negative resection margin. Chronic inflamma-
tory cell infiltration with stromal edema, telangiectasia 
and fibroblast proliferation was observed from secondary 
changes of radiation therapy (Fig. 3B). The entire para-
esophageal, subcarnial and regional lymph node areas 
were free of carcinoma except for one azygos metastatic 
lymph node. Myenteric inflammation with lymphocytic in-
filtration within the myenteric plexus was observed, and 
in particular, ganglion cells were absent (Fig. 3C). 
  The patient was discharged on the 29th postoperative 
day with no serious complications. Further postoperative 
chemotherapy was scheduled.  
DISCUSSION
  Although achalasia is a common functional disorder of 
the esophageal body and lower esophageal sphincter 
(LES), it is still a relatively rare disease. Epidemiological 
data have demonstrated an annual incidence in the range 
of 0.5 cases per 100,000 people, with a prevalence of 
about 8 cases per 100,000 people per year.
4
  The risk of esophageal malignancy for patients with 
long-standing achalasia is between 14- and 140-fold over 
the rest of the population.
3,5 A recent large cohort study 
showed male achalasia patients have substantially greater 
risk for both squamous cell carcinoma and adenocarci-
noma of the esophagus.
6 Several autopsy studies have re-
ported an esophageal carcinoma prevalence of 20-29% in 
achalasia patients,
7 and evaluation of esophagectomy 
specimens from patients with end-stage achalasia has 
demonstrated squamous hyperplasia.
8 Most likely, in the 
late phase of achalasia, chronic irritation by food and bac-
terial overgrowth causes epithelial proliferation of the 
mucosa that may progress from squamous hyperplasia to 
dysplasia and carcinoma, similar to that seen in sporadic 
esophageal squamous cell carcinoma.
9
  Apart from esophageal food stasis, the possibility of ia-332   Gut and Liver, Vol. 3, No. 4, December 2009
Fig. 3. (A) Gross specimen of 
the surgically removed esopha-
gus after concurrent chemoradia-
tion therapy. (B) Microscopic 
findings of achalasia-associated 
squamous cell carcinoma after 
concurrent chemoradiation the-
rapy. Chronic inflammatory cell 
infiltration with stromal edema, 
telangiectasia and fibroblast pro-
liferation is shown. (C) Myen-
teric inflammation with lympho-
cytes infiltration observed in the 
myenteric plexus (arrow). Gang-
lion cells are absent. 
trogenic reflux after myotomy or pneumatic dilatation has 
been also been suggested as cause of adenocarcinoma.
10 
In a Dutch study of 331 achalasia patients treated with 
pneumatic dilation, 28 (8.5%) developed endoscopical evi-
dence of Barrett’s metaplasia with intestinal metaplasia, 
seen in histological samples.
11 Other study also reported 
adenocarcinoma in Barrett’s metaplasia in achalasia.
2 
Barrett’s esophagitis is probably the result of LES 
tone-lowering therapy, which may induce significant 
sphincter insufficiency, which, in theory, may lead to 
worsened gastroesophageal reflux. 
In patients with underlying achalasia, esophageal can-
cers are generally diagnosed in advanced stages because 
the two diseases have similar symptoms, so rigorous di-
agnostic evaluation of symptoms might be undertaken 
less frequently. Patients also have a large amount of re-
tained food in the mega-esophagus, making visualization 
difficult. Therefore, reports of operability have been in-
frequent and 80% of patients are inoperable at initial 
diagnosis.
3,5 Nonetheless, whether surveillance endoscopy 
should be generally recommended for all patients with 
esophageal achalasia is still controversial because of the 
long interval between initial symptoms of achalasia and 
the development of carcinoma. A previous study on 1,062 
achalasia patients reported that the mean age at entry 
was 57.2 years and the mean age at cancer diagnosis was 
71 years.
12 Other studies also showed an interval between 
the first symptoms of achalasia and the diagnosis of 
esophageal cancer of at least 15 years.
3,5 Based on these 
observations, a recommendation of regular surveillance 
endoscopy might be beneficial in long-standing achalasia 
patients. The benefits of surveillance endoscopy in these 
patients are seen in a higher prevalence of early esoph-
ageal cancer stages.
3  
  The treatment of choice for early esophageal cancer is 
curative resection. Surgery for advanced esophageal carci-
noma has been disappointing, however, because of low 
resectability and a high risk of distant metastasis, which 
is seen in about half of the patients at the time of initial 
diagnosis.
13 Surgery has limited therapeutic effect, and 
therefore effective multimodality treatment is required to 
obtain better survival in advanced stage esophageal carci-
noma cases.
    Radiation and chemotherapy may synergistically en-
hance anti-tumor effects against esophageal cancer, so con-
current chemoradiotherapy (CRT) is an attractive strategy 
for radiosensitization and control of micrometastatic 
disease.
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with chemotherapy is superior to radiotherapy alone, based 
on the results of a number of randomized trials.
15-17  A 
landmark study by the Radiation Therapy Oncology Group 
(RTOG) compared radiation alone versus chemoradiation 
treatment (RTOG 85-01).
16 At 5 years of follow-up, the 
overall survival rates were 26% for patients who received 
combined modality treatment and 0% for those who re-
ceived radiotherapy alone. 
    Cytotoxic agents, for example 5-Fluorouracil (5-FU) 
and cisplatin, have been used as radiosensitizers in m any 
tumors, and a synergistic effect has been shown between 
the two drugs.
15,17 Based on these results, continuous 
5-FU and cisplatin can be used in concurrent chemo-
radiotherapy. In phase II studies on advanced or recurrent 
esophageal squamous cell carcinoma, this combination in-
duced a response rate of about 33-35%, leading to a me-
dian overall survival of 6-8 months, although complete re-
sponse was rare.
18,19 This case presented here also repre-
sents an excellent response to preoperative, concurrent 
chemoradiation therapy. A large main esophageal mass 
disappeared with no remaining malignant cells. We also 
observed loss of ganglion cells in the myenteric plexuses, 
surrounded by lymphocytes representing achalasia (Fig. 
3C). This inflammatory degeneration preferentially in-
volves the nitric oxide-producing, inhibitory neurons that 
induce the relaxation of esophageal smooth muscle. Thus, 
the cholinergic neurons that contribute to LES tone by 
causing smooth muscle contraction are spared.
20 
  Our case represents achalasia with squamous esoph-
ageal carcinoma and mild dysphagia, which the patient 
experienced for more than 20 years. The long duration of 
dysphagia symptoms interfered with early diagnosis of 
esophageal cancer, and long-term food stasis might have 
been a factor in the precancerous state. Although surveil-
lance endoscopy in achalasia patients is still controversial, 
periodic screening for cancer development might be advis-
able in long-standing achalasia patients. 
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